Jeffrey Rother, MD
Internal Medicine · Ardmore, OKNPI 1811951999
Payments from drug & device makers
Across 293 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$603
- AstraZeneca$548
- Novo Nordisk$544
- Sanofi-aventis U.S. LLC$540
- GSK$540
- Bayer$316
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,592100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 45 | $603 |
| AstraZeneca | 31 | $548 |
| Novo Nordisk | 35 | $544 |
| Sanofi-aventis U.S. LLC | 32 | $540 |
| GSK | 43 | $540 |
| Bayer | 22 | $316 |
| Insulet Corporation | 3 | $234 |
| AbbVie(2 entities) | 7 | $144 |
| Johnson & Johnson | 9 | $133 |
| Xeris Pharmaceuticals, Inc. | 6 | $110 |
| Merck | 8 | $99 |
| Boehringer Ingelheim | 5 | $83 |
| Pfizer | 5 | $79 |
| Amgen | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $65 |
| Abbott | 3 | $54 |
| Halozyme Inc | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 4 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Antares Pharma, Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Astellas Pharma US Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$4,592 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $176,082 |
| OzempicSemaglutide | 142 | $170,719 |
| FarxigaDapagliflozin Propanediol | 128 | $113,045 |
| JardianceEmpagliflozin | 92 | $79,691 |
| MounjaroTirzepatide | 50 | $62,139 |
| XareltoRivaroxaban | 62 | $57,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $35,496 |
| TrulicityDulaglutide | 29 | $34,760 |
| LinzessLinaclotide | 30 | $25,916 |
| JanuviaSitagliptin Phosphate | 26 | $25,037 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $23,509 |
| MyrbetriqMirabegron | 43 | $23,171 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $17,504 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $16,426 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $176,082202 claims |
| Novo NordiskOzempic | $544 | $170,719142 claims |
| AstraZenecaFarxiga, Symbicort | $548 | $117,504139 claims |
| Lilly USA, LLCMounjaro, Trulicity | $603 | $96,89979 claims |
| Boehringer IngelheimJardiance, Tradjenta | $83 | $90,671108 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $540 | $59,31886 claims |
| Johnson & JohnsonXarelto | $133 | $57,99762 claims |
| MerckJanuvia, Janumet, Dulera | $99 | $51,91570 claims |
| AbbVieLinzess | $144 | $25,91630 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $23,17143 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $540 | $12,01414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Ardmore
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.